OBJECTIVE: To evaluate whether urothelial carcinoma (UC) with sarcomatoid differentiation is associated with a lower pathological response rate to neoadjuvant chemotherapy (NAC) and worse oncological outcomes compared to UC without variant histology among patients undergoing radical cystectomy. PATIENTS AND METHODS: Patients with UC undergoing cystectomy from 1995 to 2018 at the Memorial Sloan Kettering Cancer Centre were identified. Patients with sarcomatoid differentiation at transurethral resection (TUR) or cystectomy, and patients without variant histology were selected. Downstaging from ≥cT2 to ≤pT1N0 defined partial response and pT0N0 defined complete response. Recurrence-free, cancer-specific and overall survival were modelled. RESULTS: We identified 131 patients with sarcomatoid differentiation and 1722 patients without variant histology, of whom 25 with sarcomatoid histology on biopsy and 313 without variant histology received NAC. Those with sarcomatoid differentiation presented with higher consensus tumour stage (94% ≥T2 vs 62%; P < 0.001) and were, therefore, more likely to receive NAC (29% vs 18%; P = 0.003). We found no evidence to support a difference in partial (24% vs 31%) or complete (20% vs 24%) response between patients with sarcomatoid histology and those with pure UC at TUR (P = 0.6). Among patients with sarcomatoid differentiation, 5-year recurrence-free survival was 55% (95% confidence interval [CI] 41-74) among patients receiving NAC and 40% (95% CI 31-52) among patients undergoing cystectomy alone (P = 0.1). Adjusting for stage, nodal involvement, margin status and receipt of NAC, sarcomatoid differentiation was associated with worse recurrence-free (hazard ratio [HR] 1.82, 95% CI 1.39-2.39), disease-specific (HR 1.66, 95% CI 1.23-2.22), and overall survival (HR 1.37, 95% CI 1.06-1.78). CONCLUSIONS: Sarcomatoid differentiation was associated with higher stage at presentation and independently associated with worse survival. Given similar pathological response rates if sarcomatoid differentiation is detected at initial resection, and greater survival among patients receiving NAC, treatment with NAC appears warranted. Other drivers of the poor outcomes of this histology must be investigated.
OBJECTIVE: To evaluate whether urothelial carcinoma (UC) with sarcomatoid differentiation is associated with a lower pathological response rate to neoadjuvant chemotherapy (NAC) and worse oncological outcomes compared to UC without variant histology among patients undergoing radical cystectomy. PATIENTS AND METHODS: Patients with UC undergoing cystectomy from 1995 to 2018 at the Memorial Sloan Kettering Cancer Centre were identified. Patients with sarcomatoid differentiation at transurethral resection (TUR) or cystectomy, and patients without variant histology were selected. Downstaging from ≥cT2 to ≤pT1N0 defined partial response and pT0N0 defined complete response. Recurrence-free, cancer-specific and overall survival were modelled. RESULTS: We identified 131 patients with sarcomatoid differentiation and 1722 patients without variant histology, of whom 25 with sarcomatoid histology on biopsy and 313 without variant histology received NAC. Those with sarcomatoid differentiation presented with higher consensus tumour stage (94% ≥T2 vs 62%; P < 0.001) and were, therefore, more likely to receive NAC (29% vs 18%; P = 0.003). We found no evidence to support a difference in partial (24% vs 31%) or complete (20% vs 24%) response between patients with sarcomatoid histology and those with pure UC at TUR (P = 0.6). Among patients with sarcomatoid differentiation, 5-year recurrence-free survival was 55% (95% confidence interval [CI] 41-74) among patients receiving NAC and 40% (95% CI 31-52) among patients undergoing cystectomy alone (P = 0.1). Adjusting for stage, nodal involvement, margin status and receipt of NAC, sarcomatoid differentiation was associated with worse recurrence-free (hazard ratio [HR] 1.82, 95% CI 1.39-2.39), disease-specific (HR 1.66, 95% CI 1.23-2.22), and overall survival (HR 1.37, 95% CI 1.06-1.78). CONCLUSIONS: Sarcomatoid differentiation was associated with higher stage at presentation and independently associated with worse survival. Given similar pathological response rates if sarcomatoid differentiation is detected at initial resection, and greater survival among patients receiving NAC, treatment with NAC appears warranted. Other drivers of the poor outcomes of this histology must be investigated.
Authors: Daniel J Boffa; Joshua E Rosen; Katherine Mallin; Ashley Loomis; Greer Gay; Bryan Palis; Kathleen Thoburn; Donna Gress; Daniel P McKellar; Lawrence N Shulman; Matthew A Facktor; David P Winchester Journal: JAMA Oncol Date: 2017-12-01 Impact factor: 31.777
Authors: Malte W Vetterlein; Stephanie A M Wankowicz; Thomas Seisen; Richard Lander; Björn Löppenberg; Felix K-H Chun; Mani Menon; Maxine Sun; Justine A Barletta; Toni K Choueiri; Joaquim Bellmunt; Quoc-Dien Trinh; Mark A Preston Journal: Cancer Date: 2017-07-25 Impact factor: 6.860
Authors: Nima Almassi; Eugene K Cha; Emily A Vertosick; Chun Huang; Nathan Wong; Shawn Dason; Victor McPherson; Lucas Dean; Nicole Benfante; Daniel D Sjoberg; Jonathan E Rosenberg; Dean F Bajorin; Harry W Herr; Guido Dalbagni; Bernard H Bochner Journal: J Urol Date: 2020-04-15 Impact factor: 7.450
Authors: Eliezer M Van Allen; Kent W Mouw; Philip Kim; Gopa Iyer; Nikhil Wagle; Hikmat Al-Ahmadie; Cong Zhu; Irina Ostrovnaya; Gregory V Kryukov; Kevin W O'Connor; John Sfakianos; Ilana Garcia-Grossman; Jaegil Kim; Elizabeth A Guancial; Richard Bambury; Samira Bahl; Namrata Gupta; Deborah Farlow; Angela Qu; Sabina Signoretti; Justine A Barletta; Victor Reuter; Jesse Boehm; Michael Lawrence; Gad Getz; Philip Kantoff; Bernard H Bochner; Toni K Choueiri; Dean F Bajorin; David B Solit; Stacey Gabriel; Alan D'Andrea; Levi A Garraway; Jonathan E Rosenberg Journal: Cancer Discov Date: 2014-08-05 Impact factor: 39.397
Authors: Joseph Sanfrancesco; Jesse K McKenney; Mariah Z Leivo; Sounak Gupta; Paul Elson; Donna E Hansel Journal: Arch Pathol Lab Med Date: 2016-03-31 Impact factor: 5.534
Authors: Jonathan L Wright; Peter C Black; Gordon A Brown; Michael P Porter; Ashish M Kamat; Colin P Dinney; Daniel W Lin Journal: J Urol Date: 2007-10-15 Impact factor: 7.450
Authors: Gopa Iyer; Arjun V Balar; Matthew I Milowsky; Bernard H Bochner; Guido Dalbagni; S Machele Donat; Harry W Herr; William C Huang; Samir S Taneja; Michael Woods; Irina Ostrovnaya; Hikmat Al-Ahmadie; Maria E Arcila; Jamie C Riches; Andreas Meier; Caitlin Bourque; Maha Shady; Helen Won; Tracy L Rose; William Y Kim; Brooke E Kania; Mariel E Boyd; Catharine K Cipolla; Ashley M Regazzi; Daniela Delbeau; Asia S McCoy; Hebert Alberto Vargas; Michael F Berger; David B Solit; Jonathan E Rosenberg; Dean F Bajorin Journal: J Clin Oncol Date: 2018-05-09 Impact factor: 44.544
Authors: Andrea Necchi; Daniele Raggi; Andrea Gallina; Russell Madison; Maurizio Colecchia; Roberta Lucianò; Rodolfo Montironi; Patrizia Giannatempo; Elena Farè; Filippo Pederzoli; Marco Bandini; Marco Bianchi; Renzo Colombo; Giorgio Gandaglia; Nicola Fossati; Laura Marandino; Umberto Capitanio; Federico Dehò; Siraj M Ali; Jon H Chung; Jeffrey S Ross; Andrea Salonia; Alberto Briganti; Francesco Montorsi Journal: Eur Urol Date: 2019-11-08 Impact factor: 20.096
Authors: Gopa Iyer; Christopher M Tully; Emily C Zabor; Bernard H Bochner; Guido Dalbagni; Harry W Herr; S Machelle Donat; Paul Russo; Irina Ostrovnaya; Ashley M Regazzi; Matthew I Milowsky; Jonathan E Rosenberg; Dean F Bajorin Journal: Clin Genitourin Cancer Date: 2020-03-06 Impact factor: 3.121
Authors: Brian I Rini; Robert J Motzer; Thomas Powles; David F McDermott; Bernard Escudier; Frede Donskov; Robert Hawkins; Sergio Bracarda; Jens Bedke; Ugo De Giorgi; Camillo Porta; Alain Ravaud; Francis Parnis; Enrique Grande; Wei Zhang; Mahrukh Huseni; Susheela Carroll; Roxana Sufan; Christina Schiff; Michael B Atkins Journal: Eur Urol Date: 2020-07-09 Impact factor: 24.267